SELLAS Life Sciences (SLS) Total Current Liabilities (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Total Current Liabilities for 9 consecutive years, with $10.6 million as the latest value for Q3 2024.
- Quarterly Total Current Liabilities fell 9.56% to $10.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Sep 2024, down 9.56% year-over-year, with the annual reading at $13.7 million for FY2023, 11.47% down from the prior year.
- Total Current Liabilities for Q3 2024 was $10.6 million at SELLAS Life Sciences, down from $12.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $15.5 million in Q4 2022, with the low at $3.6 million in Q1 2020.
- Average Total Current Liabilities over 5 years is $9.9 million, with a median of $11.7 million recorded in 2023.
- The sharpest move saw Total Current Liabilities crashed 59.61% in 2021, then skyrocketed 211.42% in 2022.
- Over 5 years, Total Current Liabilities stood at $12.3 million in 2020, then plummeted by 59.61% to $5.0 million in 2021, then surged by 211.42% to $15.5 million in 2022, then decreased by 11.47% to $13.7 million in 2023, then dropped by 22.73% to $10.6 million in 2024.
- According to Business Quant data, Total Current Liabilities over the past three periods came in at $10.6 million, $12.0 million, and $14.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.